PDF(Pubmed)
Abstract：
We aimed to summarize the clinicopathological characteristics and prognostic features of various molecular subtypes of diffuse gliomas (DGs) in the Chinese population.
In total, 1,418 patients diagnosed with DG between 2011 and 2017 were classified into 5 molecular subtypes according to the 2016 WHO classification of central nervous system tumors. The IDH mutation status was determined by immunohistochemistry and/or DNA sequencing, and 1p/19q codeletion was detected with fluorescence in situ hybridization. The median clinical follow-up time was 1,076 days. T-tests and chi-square tests were used to compare clinicopathological characteristics. Kaplan-Meier and Cox regression methods were used to evaluate prognostic factors.
Our cohort included 15.5% lower-grade gliomas, IDH-mutant and 1p/19q-codeleted (LGG-IDHm-1p/19q); 18.1% lower-grade gliomas, IDH-mutant (LGG-IDHm); 13.1% lower-grade gliomas, IDH-wildtype (LGG-IDHwt); 36.1% glioblastoma, IDH-wildtype (GBM-IDHwt); and 17.2% glioblastoma, IDH-mutant (GBM-IDHm). Approximately 63.3% of the enrolled primary gliomas, and the median overall survival times for LGG-IDHm, LGG-IDHwt, GBM-IDHwt, and GBM-IDHm subtypes were 75.97, 34.47, 11.57, and 15.17 months, respectively. The 5-year survival rate of LGG-IDHm-1p/19q was 76.54%. We observed a significant association between high resection rate and favorable survival outcomes across all subtypes of primary tumors. We also observed a significant role of chemotherapy in prolonging overall survival for GBM-IDHwt and GBM-IDHm, and in prolonging post-relapse survival for the 2 recurrent GBM subtypes.
By controlling for molecular subtypes, we found that resection rate and chemotherapy were 2 prognostic factors associated with survival outcomes in a Chinese cohort with DG.
In total, 1,418 patients diagnosed with DG between 2011 and 2017 were classified into 5 molecular subtypes according to the 2016 WHO classification of central nervous system tumors. The IDH mutation status was determined by immunohistochemistry and/or DNA sequencing, and 1p/19q codeletion was detected with fluorescence in situ hybridization. The median clinical follow-up time was 1,076 days. T-tests and chi-square tests were used to compare clinicopathological characteristics. Kaplan-Meier and Cox regression methods were used to evaluate prognostic factors.
Our cohort included 15.5% lower-grade gliomas, IDH-mutant and 1p/19q-codeleted (LGG-IDHm-1p/19q); 18.1% lower-grade gliomas, IDH-mutant (LGG-IDHm); 13.1% lower-grade gliomas, IDH-wildtype (LGG-IDHwt); 36.1% glioblastoma, IDH-wildtype (GBM-IDHwt); and 17.2% glioblastoma, IDH-mutant (GBM-IDHm). Approximately 63.3% of the enrolled primary gliomas, and the median overall survival times for LGG-IDHm, LGG-IDHwt, GBM-IDHwt, and GBM-IDHm subtypes were 75.97, 34.47, 11.57, and 15.17 months, respectively. The 5-year survival rate of LGG-IDHm-1p/19q was 76.54%. We observed a significant association between high resection rate and favorable survival outcomes across all subtypes of primary tumors. We also observed a significant role of chemotherapy in prolonging overall survival for GBM-IDHwt and GBM-IDHm, and in prolonging post-relapse survival for the 2 recurrent GBM subtypes.
By controlling for molecular subtypes, we found that resection rate and chemotherapy were 2 prognostic factors associated with survival outcomes in a Chinese cohort with DG.
摘要：
我们旨在总结中国人群中弥漫性胶质瘤（DGs）各种分子亚型的临床病理特征和预后特征。
总共，根据2016年WHO中枢神经系统肿瘤分类，2011年至2017年诊断为DG的1,418例患者分为5种分子亚型。通过免疫组织化学和/或DNA测序确定IDH突变状态，用荧光原位杂交检测到1p/19q共缺失。中位临床随访时间为1,076天。T检验和卡方检验用于比较临床病理特征。使用Kaplan-Meier和Cox回归方法评估预后因素。
我们的队列包括15.5%的低级别胶质瘤，IDH突变体和1p/19q缺失（LGG-IDHm-1p/19q）;18.1％低级别神经胶质瘤，IDH-突变体（LGG-IDHm）;13.1％低级别神经胶质瘤，IDH-野生型(LGG-IDHwt);36.1%胶质母细胞瘤,IDH-野生型（GBM-IDHwt）;和17.2％的胶质母细胞瘤，IDH-突变体(GBM-IDHm)。约63.3%的原发性胶质瘤，LGG-IDHm的中位总生存时间，LGG-IDHwt,GBM-IDHwt,GBM-IDHm亚型分别为75.97、34.47、11.57和15.17个月，分别。LGG-IDHm-1p/19q的5年生存率为76.54%。我们观察到在所有原发性肿瘤亚型中，高切除率与有利的生存结果之间存在显着关联。我们还观察到化疗在延长GBM-IDHwt和GBM-IDHm的总生存期中的重要作用。并延长2种复发性GBM亚型的复发后生存期。
通过控制分子亚型，我们发现,在中国DG患者队列中,切除率和化疗是2个与生存结局相关的预后因素.
总共，根据2016年WHO中枢神经系统肿瘤分类，2011年至2017年诊断为DG的1,418例患者分为5种分子亚型。通过免疫组织化学和/或DNA测序确定IDH突变状态，用荧光原位杂交检测到1p/19q共缺失。中位临床随访时间为1,076天。T检验和卡方检验用于比较临床病理特征。使用Kaplan-Meier和Cox回归方法评估预后因素。
我们的队列包括15.5%的低级别胶质瘤，IDH突变体和1p/19q缺失（LGG-IDHm-1p/19q）;18.1％低级别神经胶质瘤，IDH-突变体（LGG-IDHm）;13.1％低级别神经胶质瘤，IDH-野生型(LGG-IDHwt);36.1%胶质母细胞瘤,IDH-野生型（GBM-IDHwt）;和17.2％的胶质母细胞瘤，IDH-突变体(GBM-IDHm)。约63.3%的原发性胶质瘤，LGG-IDHm的中位总生存时间，LGG-IDHwt,GBM-IDHwt,GBM-IDHm亚型分别为75.97、34.47、11.57和15.17个月，分别。LGG-IDHm-1p/19q的5年生存率为76.54%。我们观察到在所有原发性肿瘤亚型中，高切除率与有利的生存结果之间存在显着关联。我们还观察到化疗在延长GBM-IDHwt和GBM-IDHm的总生存期中的重要作用。并延长2种复发性GBM亚型的复发后生存期。
通过控制分子亚型，我们发现,在中国DG患者队列中,切除率和化疗是2个与生存结局相关的预后因素.
